Greek price cuts put a "gravestone" over pharma sector
This article was originally published in Scrip
Executive Summary
Greece's R&D-based pharmaceutical industry has heavily criticised the government's move to introduce price-cuts ranging from 3-27% for all medicines, including the private and public sector, to save money in light of its fiscal crisis. The market decree was issued on 29 April.